Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026

About this update from Acumen Pharmaceuticals, Inc.

NEWTON, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc.  (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), will present three key studies at the upcoming Alzheimer's Association International Conference (AAIC®) 2026 in London. Shared in one oral and two poster presentations, the data highlight Acumen's progress with JCR Pharmaceuticals (JCR), in developing next generation therapeutics through Enhanced Brain Delivery (EBD) technology and expanding the field's understanding of early symptomatic AD through the patient lens. The conference will be held July 12-15, 2026, both in-person and online. "AAIC provides an important forum to share data that reflect Acumen's continued progress in advancing AβO-targeting science and our commitment to patient-centered research," said Eric Siemers, M.D., Chief Medical Officer of Acumen Pharmaceuticals. "This year's presentations include preclinical work from our collaboration with JCR evaluating our EBD technology, as well as patient-perspective research from ALTITUDE-AD that may help inform the development of future treatment approaches for early Alzheimer's disease." Acumen's presentation details are as follows: Oral Presentation Title: Bispecific Antibodies that Bind Aβ Oligomers and Transferrin Receptors Show Enhanced Brain Delivery in Cynomolgus Monkeys Date/Time: Wednesday, July 15 at 8:00 – 8:45 a.m. BST Session Name: Developing Topics in Preclinical Models Session Number: 4-7-DEV Presenting Author: Paul Shughrue, PhD, Vice President, Program Leader and Head of Research, Acumen Pharmaceuticals Poster Presentations Topic: Utilizing the Transferrin Receptor-Mediated Transport System for Enhanced Brain Delivery of anti-Aβ Oligomer Antibodies (5267) Date/Time: Monday, July 13 at 7:30 a.m. – 4:15 p.m. BST Session Title: Drug Development: Human Session Number: P2-01 Presenting Author: Erika Cline, PhD, Associate Director, Non-Clinical Development, Acumen Pharmaceuticals Topic: Understanding Early Symptomatic Alzheimer's Disease Through Patient Perspectives: Findings from the ALTITUDE-AD Trial Population (5441) Date/Time: Tuesday, July 14 at 7:30 a.m. – 4:15 p.m. BST Session Title: Dementia Care Research and Psychosocial Factors: Psychosocial and Behavioral Factors Session Number: P3-11 Presenting Author: Stephanie Cline, PhD, Health Outcomes Consultant, Acumen Pharmaceuticals Presentations from Acumen's EBD research program are part of an ongoing collaboration between Acumen and JCR announced in July 2025 . This collaboration leverages Acumen's AβO-selective antibody expertise and JCR's transferrin-receptor-targeting technology, J-Brain Cargo®, with the goal of improving drug delivery to the brain and developing a more effective treatment option with an improved safety profile to slow or prevent neurodegeneration associated with AD.

View stock analysis, news, and events for Acumen Pharmaceuticals, Inc.